DE602004017146D1 - PHARMAZEUTISCHE VERWENDUNG VON 1-AZABICYCLOi 2.2.2 OCTANEN UND VERFAHREN ZUM TESTEN VON VERBINDUNGEN AUF DIE FÄHIGKEIT ZUR AKTIVIERUNG VON INAKTIVEM WT P53 - Google Patents

PHARMAZEUTISCHE VERWENDUNG VON 1-AZABICYCLOi 2.2.2 OCTANEN UND VERFAHREN ZUM TESTEN VON VERBINDUNGEN AUF DIE FÄHIGKEIT ZUR AKTIVIERUNG VON INAKTIVEM WT P53

Info

Publication number
DE602004017146D1
DE602004017146D1 DE602004017146T DE602004017146T DE602004017146D1 DE 602004017146 D1 DE602004017146 D1 DE 602004017146D1 DE 602004017146 T DE602004017146 T DE 602004017146T DE 602004017146 T DE602004017146 T DE 602004017146T DE 602004017146 D1 DE602004017146 D1 DE 602004017146D1
Authority
DE
Germany
Prior art keywords
inactive
ability
octaneses
azabicycloi
pharmaceutical use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004017146T
Other languages
English (en)
Inventor
Staffan Stroemblad
Wenije Bao
Galina Selivanova
Natalia Issaeva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aprea Therapeutics AB
Original Assignee
Aprea AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0300812A external-priority patent/SE0300812D0/xx
Application filed by Aprea AB filed Critical Aprea AB
Publication of DE602004017146D1 publication Critical patent/DE602004017146D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
DE602004017146T 2003-03-24 2004-03-24 PHARMAZEUTISCHE VERWENDUNG VON 1-AZABICYCLOi 2.2.2 OCTANEN UND VERFAHREN ZUM TESTEN VON VERBINDUNGEN AUF DIE FÄHIGKEIT ZUR AKTIVIERUNG VON INAKTIVEM WT P53 Expired - Lifetime DE602004017146D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45652503P 2003-03-24 2003-03-24
SE0300812A SE0300812D0 (sv) 2003-03-24 2003-03-24 Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect
PCT/SE2004/000452 WO2004084893A1 (en) 2003-03-24 2004-03-24 Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53

Publications (1)

Publication Number Publication Date
DE602004017146D1 true DE602004017146D1 (de) 2008-11-27

Family

ID=33100505

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004017146T Expired - Lifetime DE602004017146D1 (de) 2003-03-24 2004-03-24 PHARMAZEUTISCHE VERWENDUNG VON 1-AZABICYCLOi 2.2.2 OCTANEN UND VERFAHREN ZUM TESTEN VON VERBINDUNGEN AUF DIE FÄHIGKEIT ZUR AKTIVIERUNG VON INAKTIVEM WT P53

Country Status (11)

Country Link
EP (1) EP1605939B1 (de)
JP (1) JP2006521375A (de)
AT (1) ATE411020T1 (de)
AU (1) AU2004224488B2 (de)
CA (1) CA2519795A1 (de)
DE (1) DE602004017146D1 (de)
DK (1) DK1605939T3 (de)
ES (1) ES2315650T3 (de)
NZ (1) NZ542212A (de)
PL (1) PL1605939T3 (de)
WO (1) WO2004084893A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400708D0 (sv) 2004-03-22 2004-03-22 Aprea Ab New compounds and use thereof
DK2525796T3 (en) 2010-01-21 2016-07-04 Aprea Ab An aqueous solution comprising 3-quinuclidinoner for the treatment of hyperproliferative disease, autoimmune disease and heart disease
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途
CN109280056A (zh) * 2017-07-21 2019-01-29 上海时莱生物技术有限公司 手性3-奎宁环酮类化合物、制备方法及用途
CN109280054A (zh) * 2017-07-21 2019-01-29 上海时莱生物技术有限公司 氘代3-奎宁环酮类化合物、制备方法及用途
EP3853227A1 (de) 2018-09-20 2021-07-28 Aprea Therapeutics AB Chinuclidin-3-on-derivate und deren verwendung zur krebsbehandlung
CA3154120A1 (en) 2019-09-18 2021-03-25 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021180338A1 (en) 2020-03-09 2021-09-16 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant
WO2022175402A1 (en) 2021-02-18 2022-08-25 Aprea Therapeutics Ab Quinuclidine-3-one derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290422B2 (en) * 2000-09-20 2006-06-15 Aprea Therapeutics Ab 1-azabicyclo(2.2.2)octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
DE60306896T2 (de) * 2002-02-21 2007-02-15 Aprea Ab Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen

Also Published As

Publication number Publication date
AU2004224488A1 (en) 2004-10-07
CA2519795A1 (en) 2004-10-07
EP1605939A1 (de) 2005-12-21
PL1605939T3 (pl) 2009-04-30
NZ542212A (en) 2008-04-30
EP1605939B1 (de) 2008-10-15
ATE411020T1 (de) 2008-10-15
ES2315650T3 (es) 2009-04-01
DK1605939T3 (da) 2009-03-09
JP2006521375A (ja) 2006-09-21
AU2004224488B2 (en) 2009-09-10
WO2004084893A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE378332T1 (de) Benzofuranderivate,verfahren zu deren herstellung und zwischenprodukte davon
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
NO20055892L (no) Karboksylsyrederivater
BR0013200A (pt) Compostos derivados de heterobiciclos contendo nitrogênio, composições farmacêuticas, método de tratamento ou prevenção de uma disfunção tromboembólica e uso dos compostos
DE60315677D1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE69931930D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
ATE411020T1 (de) Pharmazeutische verwendung von 1-azabicyclo 2.2.2 octanen und verfahren zum testen von verbindungen auf die fähigkeit zur aktivierung von inaktivem wt p53
MA28241A1 (fr) Derives d'indole hydroxyethylamine tricycliques et leur utilisation dans le traitement de la maladie d'alzheimer
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DK1194415T3 (da) Nye piperazinylalkylthiopyrimidinderivater, farmaceutiske sammensætninger indeholdende disse samt en fremgangsmåde til deres fremstilling
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
HK1087126A1 (en) Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60024997D1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE60005952D1 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
IL172134A0 (en) Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders
SE0300812D0 (sv) Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect
AR022130A1 (es) Nuevos derivados de arilalcanoilo, los procesos para su preparacion, uso y las composiciones farmaceuticas que los contienen
ATE422500T1 (de) Neue chelidonin-derivate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition